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SUMMARY
Two zoonotic coronaviruses (CoV), SARS-CoV and MERS-CoV have crossed species to cause 
severe human respiratory disease. Here, we showed that induction of airway memory CD4+ T cells 
specific for a conserved epitope shared by SARS-CoV and MERS-CoV is a potential strategy for 
developing pan-coronavirus vaccines. Airway memory CD4+ T cells differed phenotypically and 
functionally from lung-derived cells and were crucial for protection against both CoVs in mice. 
Protection was interferon-γ-dependent and required early induction of robust innate and virus-
specific CD8+ T cell responses. The conserved epitope was also recognized in SARS-CoV and 
MERS-CoV-infected human leukocyte antigen DR2 and DR3 transgenic mice, indicating potential 
relevance in human populations. Additionally, this epitope was cross-protective between human 
and bat CoVs, the progenitors for many human CoVs. Vaccine strategies that induce airway 
memory CD4+ T cells targeting conserved epitopes may have broad applicability in the context of 
new CoV and other respiratory virus outbreaks.
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 INTRODUCTION
The coronavirus (CoV) Middle East Respiratory Syndrome (MERS)-CoV is a newly 
emerging pathogen that continues to cause outbreaks in the Arabian peninsula and in 
travelers from this region. As of April 24, 2016, 1724 cases with 623 deaths (36.1% 
mortality) were reported to the World Health Organization. Another human pathogenic CoV, 
Severe Acute Respiratory Syndrome (SARS-CoV), caused greater than 8000 human 
infections in 2002-2003, with a 10% mortality rate (Peiris et al., 2004). The presence of 
SARS-like CoV and other CoVs in zoonotic populations as well as the ongoing MERS 
epidemic, make it likely that additional CoV outbreaks will emerge (Ge et al., 2013). These 
possibilities indicate the need for development of vaccines that would be effective against 
many strains of CoVs.
Most CoV vaccines presently under development target the most variable part of the spike 
glycoprotein and induce antibody responses only against the virus present in the vaccine. 
However, even that virus can undergo antibody escape (Ma et al., 2014; Sui et al., 2014). 
Antibody responses in patients previously infected with respiratory viruses, including 
SARS-CoV and influenza A virus (IAV) tend to be short-lived (Channappanavar et al., 2014; 
Wilkinson et al., 2012). On the other hand, T cell responses often target highly conserved 
internal proteins, and are long-lived. SARS-CoV-specific memory T cells but not B cells 
could be detected 6 years after infection in SARS survivors (Tang et al., 2011). Further, IAV-
specific memory CD4+ T cell numbers correlated with protection against the influenza strain 
H1N1 infection during the 2009 epidemic (Wilkinson et al., 2012).
Memory CD4+ T cells are more numerous at sites of infection than CD8+ T cells (Turner 
and Farber, 2014) and have multiple roles in initiating and propagating the immune response 
(Swain et al., 2012). However, much less is known about how these cells provide protection 
and whether localization of these cells at specific sites within tissue is critical (Turner and 
Farber, 2014). In the respiratory tract, memory CD4+ T cells include cells in the airway and 
parenchyma and cells adhering to the pulmonary vasculature. Airway memory CD4+ T cells 
are the first cells to encounter viral antigen during respiratory infections, suggesting a key 
role in protection. However, it is not clear whether airway and parenchymal cells 
differentially mediate protection during respiratory infections.
Here, we show that intranasal vaccination with Venezuelan equine encephalitis replicons 
(VRP) encoding a SARS-CoV CD4+ T cell epitope induces airway CoV-specific memory 
CD4+ T cells that efficiently protected mice against lethal disease through rapid local IFN-γ 
production. The epitope used was conserved in MERS-CoV, was presented by human 
leukocyte antigen (HLA) DR2 and DR3 molecules and mediated cross protection between 
SARS-CoV and MERS-CoV and related bat CoV. These results indicate that induction of 
airway memory CD4+ T cells should be considered as a component of any universal human 
coronavirus vaccine and potentially, those targeting other respiratory viruses.
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 RESULTS
 Intranasal vaccination with VRP-SARS-N results in CD4+ T cell-dependent protection 
against SARS-CoV
Previously, we identified a dominant CD4+ T cell epitope in the nucleocapsid (N) protein of 
SARS-CoV (N353) recognized in BALB/c (H-2d) mice; no CD8+ T cell epitopes are present 
in this protein (Zhao et al., 2010). This region of N is also targeted by CD4+ T cells from 
SARS convalescent patients (Oh et al., 2011; Peng et al., 2006). We initially evaluated 
whether intranasal (i.n.) immunization, which generates local CD4+ T cell responses, or 
footpad vaccination, which generates a systemic T cell response, resulted in differences in 
protection against challenge with mouse-adapted SARS-CoV (Roberts et al., 2007). For this 
purpose, we vaccinated BALB/c mice twice at 6–7 week intervals with VRP-SARS-N or a 
control VRP expressing green fluorescent protein (VRP-GFP) i.n. or subcutaneously (s.c.) 
prior to challenge. VRPs are non-replicating vaccine vectors that preferentially infect human 
and mouse dendritic cells and serve as self-adjuvants (Moran et al., 2005; Tonkin et al., 
2012). Only i.n. inoculation with VRP-SARS-N induced an N-specific CD4+ T cell response 
in the lungs and airways, which was increased by i.n VRP-SARS-N boosting (Figure 1A). In 
contrast, s.c. inoculation resulted in a CD4+ T cell response primarily in the spleen with 
virtually no N-specific T cells identified in the lungs or airway. Subcutaneous boosting 
increased the numbers of virus-specific cells in the spleen but not in respiratory tissue. As 
expected, VRP-SARS-N administration resulted in accumulation of N-expressing DCs and, 
consequently, more N-specific CD4+ T cells in the draining mediastinal lymph nodes (MLN; 
i.n. immunization) and popliteal lymph nodes (PLN; s.c. immunization) (Figure S1). 
Protection from lethal disease was nearly complete after i.n. but not s.c. administration of 
VRP-SARS-N, demonstrating the importance of the route of vaccination (Figure 1B). 
Protection was observed against challenge with doses ranging from 100–10,000 PFU of 
SARS-CoV (Figure 1C). By days 4-6 after challenge, SARS-CoV-infected VRP-GFP-
immunized mice develop severe edema with a relative paucity of infiltrating cells while 
intranasal VRP-SARS-N immunized mice displayed prominent peribronchiolar and 
perivascular infiltration and minimal amounts of edema in the lungs. Subcutaneous 
immunization with VRP-SARS-N did not protect against edema formation (Figure 1D). 
Consistent with these results, intranasal VRP-SARS-N immunization enhanced the kinetics 
of virus clearance (Figure 1E). Next we assessed the role of memory CD4+ T cells in 
protection by depleting them systemically 2 days prior to challenge. This abrogated 
protection (Figure 1F, Figure S2A), indicating that memory CD4+ T cells may be important 
for protection.
In a subsequent set of experiments, to confirm the importance of memory CD4+ T cells, 
vaccinated mice were treated with CD4+ T cell-depleting antibody 98 days prior to 
challenge to allow CD4+ T cell recovery (Figure S2B). These mice were not protected 
against SARS-CoV challenge (Figure 1F) and developed histological changes similar to 
those observed in VRP-GFP-immunized mice (Figure 1G). N-specific CD4+ T cell numbers 
gradually decreased after vaccination (Figure 1H), but still mediated partial protection after 
challenge at 41 weeks post boosting (Figure 1I). CD4+ T cells provide helper function for 
antibody production, but unlike sera from VRP-SARS-S, which induced neutralizing 
Zhao et al. Page 3
Immunity. Author manuscript; available in PMC 2017 June 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
antibody, sera from VRP-SARS-N-immunized mice were not protective upon transfer to 
naïve mice prior to challenge (Figure 1J). Protection was also observed in mice immunized 
with another vaccine, recombinant vaccinia virus expressing the N protein (rVV-SARS-N) 
(Figure 1K). As the CD4+ T cell response was more robust in VRP compared to rVV 
immunized mice (data not shown), we used VRP-SARS-N for the remainder of the 
subsequent experiments. 12 month old mice are very susceptible to SARS-CoV (Zhao et al., 
2011); however, VRP-SARS-N vaccination at 12 month and analysis at 15 month of age 
resulted in protection against challenge demonstrating efficacy even in this highly vulnerable 
population (Figure 1L). Together, these results indicate that intranasal but not subcutaneous 
immunization induced a protective CD4+ T cell immune response.
 Airway-derived N-specific CD4+ T cells are superior effector cells
While these results demonstrated that SARS-CoV N specific memory CD4+ T cells in the 
respiratory tract were protective, they did not distinguish between cells localized in the 
airway, parenchyma and vasculature. To discriminate between cells localized to the airway 
versus those in the parenchyma and vasculature, we used a modification of a previously 
described method (Anderson et al., 2012) to simultaneously label cells by i.v. and i.n. 
administration of CD90.2 and CD45 antibodies, respectively, 5–7 weeks post boosting. 
Consistent with CD8+ T cell studies, a large proportion of CD4+ T cells in the respiratory 
tract were localized in the vasculature (Anderson et al., 2012) (Figure 2A). Additionally, the 
vast majority of cells in the airway were not labeled by i.v. antibody administration, 
indicating their anatomic compartmentalization (Figure 2A). N353-specific CD4+ T cells 
comprised a higher percentage of cells in the airway compared to the parenchymal or 
vascular populations, although the greatest number of SARS-CoV specific cells were present 
in the vasculature (Figure 2B). Airway, parenchymal and vascular N353 memory CD4+ T 
cells differed phenotypically. Surface molecules associated with memory (CD127 and 
CD27) and trafficking (CD11a) were expressed at lower levels on airway cells compared to 
cells in the parenchyma or vasculature. Unlike memory CD8+ T cells localized in tissues, 
airway memory CD4+ T cells did not express CD69, CD103 and Ly6C although CD69 was 
expressed after priming (data not shown). Parenchymal cells expressed CD103 and Ly6C 
(Figure 2C) (Mueller et al., 2013).
Next, we examined whether cells in the airway, which first encounter viral antigen, were 
critical for mediating protection after challenge. After SARS-CoV challenge, the percentage 
of N-specific CD4+ T cells was much higher in the airway and the number of N353 CD4+ T 
cells at this site increased substantially compared to those in the parenchyma and vasculature 
(Figure 2D). Also, airway N353 CD4+ T cells expressed IFN-γ at higher levels on a per cell 
basis compared to the parenchyma and vasculature (Figure 2D, E). Airway cells had 
superior effector function, indicated by the ability to express more than one cytokine (TNF, 
IL-10, IL-2) (Figure 2E). In addition, these multi-functional CD4+ T cells were present at a 
higher frequency in the airway compared to parenchyma and vasculature (Figure 2F), and 
exhibited greater functional avidity (Figure 2G). To determine whether the increase in N353 
CD4+ T cells reflected local proliferation or recruitment, infected mice were treated with 
FTY720 to prevent T cell egress from lymphoid tissue and then treated at day 4 p.i. with 
BrdU for 4 hours (Figure S3). FTY720 treatment decreased the numbers of N-specific CD4+ 
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T cells in the respiratory tract and the remaining cells showed evidence of BrdU 
incorporation, indicating roles for both recruitment and proliferation in augmentation of 
N353 CD4+ T cells. These results indicate that memory CD4+ T cells in the airway were 
phenotypically and functionally different from those in the parenchyma and vasculature, 
were maintained by both local proliferation and recruitment and were potentially most 
important for protection.
 N-specific airway memory CD4+ T cells mediate protection by local expression of IFN-γ
To address more explicitly the role of airway cells in protection, we depleted CD4+ T cells 
in the airways, but not the parenchyma or vasculature, by i.n. administration of 10 μg anti-
CD4+ T cell antibody prior to challenge (Figure 3A). Previous reports indicated a key role 
for resident memory T (Trm) cells (T cells that are present at sites of prior infection without 
recirculation) in protection against pathogen challenge (Masopust and Picker, 2012; Mueller 
et al., 2013; Turner and Farber, 2014) and CD4+ Trm cells have been identified in the 
context of influenza A virus infection (Teijaro et al., 2011). However, these airway N353 
cells did not fit the classic definition of resident memory T cells because they were 
replenished by 4 weeks after depletion (Figure 3B), similar to airway memory IAV-specific 
CD8+ T cells (Slutter et al., 2013). Depletion decreased survival to approximately 35%, 
demonstrating the key role that airway memory CD4+ T cells have in protection (Figure 3C). 
To probe the mechanism of action of these cells, we initially focused on Type I interferon 
(IFN-I) expression since IFN-I orchestrates a protective response at early times p.i. IFN-α, 
IFN-β and IFN-λ were not upregulated after VRP-SARS-N immunization. In contrast, 
higher IFN-γ mRNA levels were detected in the lungs of VRP-SARS- N immunized mice by 
day 1 p.i. (Figure 3D, E). This cytokine was largely produced by airway CD4+ T cells since 
local and systemic depletion of these cells was equally efficient in reducing IFN-γ 
expression in the lung (Figure 3E). Expression of other cytokines, such as TNF, IL-1β, IL-6 
and IL-12, was not upregulated by prior VRP-SARS-N vaccination (Figure S4A). IFN-γ 
expression by airway CD4+ T cells was confirmed using an in vivo cytokine expression 
assay, in which mice were treated with Brefeldin A (BFA) for 6 hours prior to direct ex vivo 
analysis without additional stimulation (Hufford et al., 2011) (Figure 3F). Expression of 
IFN-γ by CD4+ T cells resulted in the upregulation of several IFN-related genes in SARS-
CoV-challenged, VRP- SARS-N-vaccinated mice, including STAT-1, PKR and OAS-1, 
which are important for CoV clearance (Frieman et al., 2010; Wang et al., 2009; Zhao et al., 
2012) (Figure S4B). Neutralization of IFN-γ in the airway by i.n. administration prior to 
infection and every 2 days thereafter abrogated upregulation of these genes (Figure 3G).
Airway IFN-γ neutralization resulted in increased mortality (Figure 3H) and also in an 
increase in pathological changes (i.e., edema, alveolar destruction) in the lungs (Figure 3I). 
Both airway CD4+ T cells and IFN-γ were required for maximal kinetics of virus clearance 
(Figure 3J), emphasizing the key role that these cells and cytokine played in protection, 
which was confirmed by demonstrating that airway administration of IFN-γ (but not TNF) 
resulted in 100% survival after SARS-CoV challenge (Figure. 3K). Collectively, these 
results indicate that airway memory CD4+ T cells were replenished from the lungs or 
periphery and that their protective function was largely mediated by IFN-γ.
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 Airway CD4+ T cell-derived IFN-γ is required for optimal respiratory dendritic cell 
migration to MLN
While airway memory CD4+ T cells and IFN-γ activated the innate immune response, virus 
clearance was also accelerated at late times p.i. (Figure 1E, Figure 3J). This suggested that 
these cells had an additional role in enhancing the adaptive immune response, most likely 
the virus-specific CD8+ T cell response, critical for SARS-CoV clearance (Channappanavar 
et al., 2014; Zhao et al., 2010). To generate robust CD8+ T cell responses, respiratory 
dendritic cells (rDCs) must migrate to MLN and prime naïve CD8+ T cells(Zhao et al., 
2011). We next assessed whether airway memory CD4+ T cells participated in these 
processes. In a role not previously reported, IFN-γ, largely expressed by these airway CD4+ 
T cells was critical for optimal rDC migration, as measured by increased frequency and 
number of lung- derived carboxyfluorescein succinimidyl ester (CFSE)-labeled rDCs in the 
MLN compared to VRP-GFP immunized mice (Figure 4A). Administration of anti-CD4 or 
anti-IFN-γ antibody i.n. significantly reduced rDC migration to the MLN, accompanied by 
decreased accumulation of total lymph node cells (Figure 4B). These rDCs in MLN were 
mature and optimized for antigen presentation as shown by expression of co-stimulatory 
molecules such as CD40, CD80 and CD86. rDC migration to the MLN requires CCR7 
expression and CCR7 was also upregulated on migratory rDCs in the MLN (Figure 4C). 
IFN-γ augmented CCR7 expression since i.n. IFN-γ treatment resulted in a tenfold increase 
in the frequency of lung CCR7+ rDCs (Figure 4D). Together, these results established that 
airway memory CD4+ T cells and IFN-γ secreted by these cells, in addition to activating the 
innate immune response, enhanced rDC migration to the MLN.
 Airway CD4+ T cell-derived IFN-γ promotes CXCR3-dependent CD8+ T cell mobilization 
to infected lung
SARS-CoV challenge of VRP-SARS-N immunized mice resulted in an increase in 
frequency and numbers of lung CD8+ T cells that recognized epitope S366 (the dominant 
epitope in BALB/c mice) when compared to VRP-GFP-immunized mice (Figure 5A). These 
CD8+ T cells were functional, as shown by upregulation of granzyme B and CD107 (Figure 
5B). We confirmed that these cells were cytotoxic in vivo by showing that i.n. delivered 
peptide S366-coated target cells were specifically lysed in the lungs of immunized but not 
control mice (Figure 5C). Depletion of CD8+ T cells prior to challenge resulted in decreased 
survival (Figure 5D, Figure S2A) and delayed virus clearance at late times p.i. (Figure 5E).
To assess the role of airway memory CD4+ T cells in this enhanced CD8+ T cell response, 
we depleted airway CD4+ T cells or IFN-γ using antibodies and observed a decreased 
frequency and number of virus-specific CD8+ T cells in the lungs (Figure 5F). Accumulation 
of cells in the lung requires T cell migration to this site, a process that is chemokine-
dependent. Virus-specific CD8+ T cells expressed chemokine receptor CXCR3 but not 
CCR4 and CCR5 (Figure 5G), suggesting that effector CD8+ T cell entry into the infected 
lung was dependent upon the CXCR3 pathway. In support of this, CXCR3 ligands CXCL9, 
CXCL10 and CXCL11, were expressed in the infected lungs in an airway CD4+ T cell and 
IFN-γ-dependent manner (Figure 5H, Figure S4C). We directly confirmed the importance of 
CXCR3 in CD8+ T cell accumulation in the lungs by systemic blockade of CXCR3 at days 3 
and 5 p.i. This treatment decreased the frequency and numbers of epitope S366-specific 
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CD8+ T cells in the lungs. Together these results showed that airway memory CD4+ T cells 
orchestrated both rDC migration to the MLN and virus-specific CD8+ T cell trafficking to 
the lungs, enhancing clinical outcomes.
 IL-10 produced by airway CD4+ T cells is required for optimal protection
T cell-derived IL-10 is important for reducing immunopathology in infected mice (Sun et 
al., 2009; Trandem et al., 2011). However, IL-10 is not produced by T cells in SARS-CoV-
infected mice (Zhao et al., 2010), which may contribute to more severe disease. In contrast, 
i.n. VRP-SARS-N vaccination induced IL-10 expression by SARS-N353-specific CD4+ T 
cells in the lung after direct ex vivo stimulation (Figure 2E, F) or in vivo (Figure S5A–C). 
IL-10 expression in the lungs was partly CD4+ T cell and IFN-γ-mediated (Figure S5A, B). 
IL-10 contributed to improved outcomes in VRP-SARS-N immunized mice because IL-10 
receptor blockade decreased survival (Figure S5D), without affecting the kinetics of virus 
clearance (Figure S5E). Thus, airway memory CD4+ T cells expression of both pro-
inflammatory (IFN-γ) and anti-inflammatory molecules was required for optimal protection.
 VRP-SARS-N immunization does not result in increased eosinophil infiltration into the 
lungs
Previous studies of alum-adjuvanted killed SARS-CoV vaccines sometimes described 
eosinophilic infiltration into the lungs after challenge, suggestive of immunopathological 
disease (Bolles et al., 2011; Iwata-Yoshikawa et al., 2014). However, we could find no 
evidence of an eosinophilic infiltration into the lungs of either young or aged mice after i.n. 
or s.c. VRP-SARS-N immunization and challenge, when compared to mice vaccinated with 
a control VRP (Figure 1D, Figure S6).
 MERS-CoV N350 CD4+ T cell epitope elicits a protective response in BALB/c and HLA 
transgenic mice
Having established that airway memory CD4+ T cells mediated protection against SARS-
CoV challenge, we next assessed whether this approach was broadly applicable to other 
CoV infections, including MERS-CoV. First, we examined N proteins from several alpha 
and beta coronaviruses for a SARS-N353 epitope-like sequence. Epitope SARS-N353 was 
present in all SARS-like CoV isolated from civet cats, Chinese ferret badgers and bats. Bats 
are the reservoir for SARS-CoV while civet cats and Chinese ferret badgers served as 
intermediate hosts during the 2002–2003 pandemic (2004; Ge et al., 2013; Li et al., 2005). 
In addition, similar sequences were detected in MERS-CoV and bat CoV HKU4, HKU5 and 
HKU9 as well as more distantly related alphacoronaviruses (Figure 6A). To determine 
whether MERS-N350 was recognized in infected mice, we challenged mice expressing the 
virus receptor, hDPP4 (human dipeptidyl peptidase 4) (Zhao et al., 2014) with MERS-CoV. 
MERS-N350-specific CD4+ T cells were detected in infected BALB/c mice (Figure 6B). 
Next, mice were immunized with VRP-MERS-N, resulting in a robust airway CD4+ T cell 
response that could be boosted by a second VRP-MERS-N immunization (Figure 6C). 
Consistent with results obtained after VRP-SARS N vaccination, these cells exhibited 
superior effector function, were multifunctional (Figure S7) and accelerated virus clearance 
upon challenge (Figure 6D). MERS-CoV N, unlike SARS-CoV N protein, encodes a weak 
CD8+ T cell epitope in BALB/c mice (N214, LYLDLLNRL) (Zhao et al., 2014), which may 
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have contributed to accelerated virus clearance. However, the contribution made by these 
cells was relatively minor as depletion of airway CD4+ T cells or blockade of airway IFN-γ 
significantly decreased the rate of virus clearance (Figure 6E).
The region of the N protein encoding SARS-N353 was recognized in some SARS patients 
(Oh et al., 2011; Peng et al., 2006). To determine whether the SARS-N353 or MERS-N350 
epitope was potentially recognized in humans, we immunized mice transgenic for human 
HLA class II DR2 or DR3 antigen with N peptides and analyzed mice for peptide-specific 
CD4+ T cell responses. As shown in Figure 6F, SARS-N353 could be presented by both 
DR2 and DR3, while MERS-N350 was successfully presented by DR2. HLA-DR2 and 
HLA-DR3 transgenic mice are on a C57BL/10 (H-2b) background. Young SARS-CoV 
infected mice on this background do not develop clinical disease (Frieman et al., 2010; Zhao 
et al., 2011), so we assessed the effect of immunization by measuring the kinetics of virus 
clearance. Immunization with VRP-SARS-N or VRP-MERS-N enhanced the kinetics of 
virus clearance from these HLA transgenic mice after challenge with SARS-CoV or MERS-
CoV (Figure 6G), indicating that these constructs could be potential vaccine candidates in 
human populations. No H-2b-restricted CD8+ T cell epitopes are present in the N protein of 
either MERS-CoV or SARS-CoV (Zhao et al., 2014; Zhao et al., 2010) so that vaccination 
induced solely a virus-specific CD4+ T cell response.
 Cross-reactive CD4+ T cells are protective against SARS-CoV and MERS-CoV
Neutralizing antibodies against SARS-CoV and MERS-CoV are not cross-reactive in 
humans or mice (Agnihothram et al., 2014) as these antibodies are directed against the 
highly variable S protein. Having identified closely related analogues to SARS-N353 in 
other coronaviruses (Figure 6A), we next asked whether these epitopes induced cross-
reactive memory CD4+ T cells in the airway. Immunization with VRP-MERS-N induced 
CD4+ T cells that responded to many of the peptides listed in Figure 6A (Fig 7A), whereas 
VRP-SARS-N immunization induced a small cross-reactive response (<1.0%, data not 
shown). Next, we assessed whether these VRP-MERS-N-induced cross-reactive memory 
CD4+ T cells were protective against SARS-CoV challenge. After VRP-MERS-N 
immunization and SARS-CoV challenge, virus-specific airway CD4+ T cells were detected 
after stimulation with either SARS-N353 or MERS-N350 peptides; these cells were not 
present in infected mice previously immunized with VRP-GFP (Figure 7B). VRP-MERS-N 
vaccination was partly protective against low dose SARS-CoV challenge (Figure 7C). This 
limited protection was most likely because the numbers of cross-reactive N-specific CD4+ T 
cells in the airway were approximately tenfold lower than detected after VRP-SARS-N 
immunization (compare Figures 1A and 7B). As we observed strong cross-reactivity 
between the MERS-CoV and HKU4 and HKU5 epitopes, we examined whether vaccination 
with VRP-HKU4-N would enhance MERS-CoV clearance. Vaccination with VRP-HKU4-N 
induced cross-reactive CD4+ T cell responses against MERS-CoV N and HKU5 N (Figure 
7D). After challenge with MERS-CoV, we detected a robust CD4+ T cell response, with 
more cells responding to MERS-N350 than to HKU4-N351 (Figure 7E). VRP-HKU4-N 
vaccination resulted in enhanced MERS-CoV clearance, with kinetics very similar to that 
observed after VRP-MERS-N vaccination (compare Figures 6D and 7F). Collectively, these 
results indicate that a conserved epitope recognized by airway memory CD4+ T cells in 
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SARS-CoV and MERS-CoV-infected mice induced a cross-reactive, protective immune 
response.
 DISCUSSION
No licensed vaccines are available for either SARS-CoV or MERS-CoV, two pathogenic 
human coronaviruses and none of the vaccines under development have broad activity. Here 
we showed that respiratory tract memory CD4+ T cells provided protection against challenge 
with SARS-CoV and MERS-CoV. Using specific depletion of CD4+ T cells by i.n. 
administration of antibody, we demonstrated that cells localized to the airway were critical 
for protection. Airway CoV-specific CD4+ T cells provided the first line of defense against 
challenge, enhancing the immune response at early and late times p.i. More rapid virus 
clearance occurred within 1–2 days after challenge, demonstrating the role of airway 
memory CD4+ T cells in enhancing the innate immune response. At 6–7 days p.i., virus 
clearance was again accelerated because these cells augmented rDC migration to MLN and 
subsequent virus-specific CD8+ T cell priming and mobilization to the infected lungs in a 
CXCR3-dependent manner. All of these effects were dependent upon airway CD4+ T cell-
derived IFN-γ.
As in humans and other animals infected with coronaviruses, CD4+ T cell epitopes 
recognized in IAV-infected humans and mice are highly conserved (MacLeod et al., 2010) 
and elicit protective responses. Protection occurs via IFN-γ expression, and enhancement of 
CD8 T cell and antibody responses, similar to our findings (McKinstry et al., 2012). In 
another study, memory CD4+ T cells were identified in the lungs of IAV-infected mice and 
shown to be lung-resident cells using a parabiosis model. After transfer to naïve mice, these 
lung-derived cells mice preferentially migrated to the lungs and mediated protection upon 
subsequent IAV challenge (Teijaro et al., 2011). IAV-specific memory CD4+ T cells also 
were identified in normal appearing human lungs (Purwar et al., 2011). While both of these 
studies refer to these cells as lung CD4+ Trm cells, our results suggest that this terminology 
must be used carefully. We showed that there were three populations of cells in the lungs, 
and at least memory CD4+ T cells in the airways were replenished after a few weeks. 
Memory CD4+ T cells have specific advantages compared to memory CD8+ T cells because 
they are longer lived in some settings and are more polyclonal (Lees and Farber, 2010; 
Stockinger et al., 2006). Consistent with this, we observed that the SARS-N353-specific 
CD4+ T cell response in the airway demonstrated long term protection as mice immunized 
with VRP-SARS-N at six weeks of age and challenged 41 weeks after boosting exhibited 
30% survival while age matched controls all succumbed to the infection. Further, CD4+ T 
cell epitopes are less prone to immune escape than are CD8+ T cell epitopes, partly because 
CD4+ T cells largely function via CD8+ T cell recruitment and other indirect mechanisms 
while virus-specific CD8+ T cells directly target infected cells. Consequently, CD4+ T cell 
epitope escape has only rarely been described (Harcourt et al., 1998).
We observed that airway, parenchymal and vascular memory CD4+ T cells differ 
phenotypically and functionally. First, CD127 and CD27, two memory T cell markers 
(Mueller et al., 2013), were present at lower levels on airway CD4+ T cells, suggesting that 
these cells maintained an effector-like phenotype and were delayed in transition to a 
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complete memory phenotype. Second, CD11a, important for retention in tissues, was lower 
on airway CD4+ T cells, indicating a lack of requirement for tissue adherence and consistent 
with localization in the airway. Third, airway CD4+ T cells did not express CD103, CD69 
and Ly6C, markers for CD8+ Trm cells, unlike parenchymal cells, which resembled CD8+ 
Trm cells more closely. Finally, airway CD4+ T cells were more multifunctional than cells in 
the parenchyma and vascular, with a higher percentage of cells producing multiple cytokines 
and with higher cytokine production on a per cell basis. Airway cells exhibited greater 
functional avidity than their parenchyma counterparts, arguing that they could rapidly 
respond at early stages during pathogen challenge while antigen levels were still low.
The N protein is conserved among different coronaviruses and induces cross-reacting 
antibodies (Woo et al., 2004). However, N-specific sera were non-neutralizing and did not 
protect against subsequent challenge, as shown in this report and by others (Agnihothram et 
al., 2014). In contrast, airway memory CD4+ T cells targeting SARS-CoV epitope N353 or 
its homologue in MERS-CoV and other CoV induced protective responses. The MERS-CoV 
and HKU4 N-specific epitopes induced especially strong cross-reactive and protective 
responses so their inclusion in a vaccine would be expected to increase efficacy against a 
variety of antigenically variable human coronaviruses. Studies of SARS survivors (Oh et al., 
2011; Peng et al., 2006), as well as our analyses of infected DR2 and DR3 Tg mice indicated 
that this epitope was also likely to be useful as an immunogen in human populations.
In summary, intranasal vaccine administration generated memory CD4+ T cells that were 
localized to the airway and were more protective against challenge with pathogenic human 
coronaviruses than those generated after systemic vaccination. The combination of memory 
CD4+ T cell-inducing vaccines with those able to elicit strong neutralizing antibody 
responses and memory CD8+ T cells would be predicted to result in long lasting, broad 
protection against several CoVs. This strategy may also be useful in the context of other 
pathogenic respiratory viruses.
 EXPERIMENTAL PROCEDURES
 Mice, virus and cells
Specific pathogen-free mice were maintained in the Animal Care Facility at the University 
of Iowa. All protocols were approved by the University of Iowa Institutional Animal Care 
and Use Committee. The EMC/2012 strain of MERS-CoV (passage 8, designated MERS-
CoV) was provided by Drs. Bart Haagmans and Ron Fouchier (Erasmus Medical Center). 
Mouse-adapted SARS-CoV (MA15) was a kind gift from Dr. Kanta Subbarao (N.I.H., 
Bethesda, Maryland) (Roberts et al., 2007). All work with SARS-CoV and MERS-CoV was 
conducted in the University of Iowa Biosafety Level 3 (BSL3) Laboratory.
 Venezuelan Equine Encephalitis Replicon particles (VRPs) and mouse immunization
VRPs expressing the SARS-CoV, MERS-CoV or HKU4 nucleocapsid proteins (N) were 
constructed as previously described(Scobey et al., 2013; Zhao et al., 2014). Mice were 
primed and boosted (6–7 weeks after priming) with 1x105 Infectious Units (IU) of VRP-
SARS-N, VRP-SARS-S or VRP-GFP in the left footpad in 20 μl PBS or intranasally (i.n.) in 
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50 μl PBS after light anesthesia with isoflurane. Mice were challenged with SARS-CoV or 
MERS-CoV 4–6 weeks post boosting.
 Transduction and infection of mice
Recombinant adenoviral vectors expressing-hDPP4 (Ad5-DPP4) were prepared and used as 
previously described(Zhao et al., 2014). Mice were infected with indicated doses of MERS-
CoV or SARS-CoV in 50 μl DMEM.
 Preparation of cells from bronchoalveolar lavage fluids (BALF), lungs and mediastinal 
lymph nodes (MLN)
Mice were sacrificed at the indicated time points. BALF was acquired by inflating lungs 
with 1 ml complete RPMI 1640 medium via cannulation of the trachea followed by lavaging 
4 times. Cells in the BALF were collected by centrifugation. Cells were prepared from the 
lungs and MLN as previously described(Zhao et al., 2011).
 Simultaneous intranasal/intravascular antibody labeling
Mice were lightly anesthetized with isoflurane and treated i.n. with 0.25 μg fluorochrome-
conjugated CD45 antibody in 100 μl PBS. After 2 minutes, mice were injected i.v. with 0.5 
μg of fluorochrome-conjugated CD90.2 antibody for an additional 3 minutes prior to 
euthanasia as previously described(Anderson et al., 2012). Mice were perfused and cells 
from the airway and lungs were prepared.
 Antibody and cytokine treatment
For systemic depletion of CD4+ or CD8+ T cells, mice were injected intraperitoneally (i.p.) 
with 1 mg anti-CD4 antibody (clone GK1.5) or 500 μg anti-CD8 antibody (clone 2.43), 
respectively at days -2 and 0 p.i. For airway depletion of CD4+ T cells, mice were lightly 
anesthetized with isoflurane and treated with 10 μg anti-CD4 antibody i.n. in 75 μl PBS at 
day -1 p.i. For systemic neutralization/blockade of IFN-γ and IL-10, mice were injected i.p. 
with 500 μg of anti-IFN-γ antibody (clone XMG1.2) or anti-IL-10 receptor antibody (clone 
1B1.3A) at day -2, 0, 2, 4, 6, 8 p.i. For airway neutralization of IFN-γ, mice were treated i.n. 
with 10 μg of anti-IFN-γ antibody (clone XMG1.2) at day −2, 0, 2, 4, 6, 8 p.i., respectively. 
CXCR3 was blocked with i.p. injection of 500 μg of anti-CXCR3 antibody (clone 
CXCR3-173) at days 3 and 5 p.i. Control mice received equivalent doses of rat or Armenian 
Hamster IgG in each experiment. All antibodies were acquired from Bio X cell (West 
Lebanon, NH). For cytokine treatment, mice were treated with 200 ng rIFN-γ or rTNF 
(R&D Systems, McKinley Place, NE) intranasally in 50 μl PBS 12 hours before infection.
 Statistical analysis
A Student's t test was used to analyze differences in mean values between groups. All results 
are expressed as means ± standard errors of the means (SEM). P values of <0.05 were 
considered statistically significant.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Intranasal vaccination with VRP-SARS-N results in CD4+ T cell-dependent protection 
against lethal SARS-CoV infection
6 week-old BALB/c mice were vaccinated with VRP-GFP or VRP-SARS-N in the footpad 
(subcutaneously, s.c.) or intranasally (i.n.) and boosted 6–7 weeks later. (A) Vaccinated mice 
were infected with SARS-CoV at the indicated times. Cells from airway, lung and spleen 
were stimulated with SARS-N353 peptide. Numbers of IFN-γ+ CD4+ T cells are shown. (B) 
Survival after infection with 500 PFU SARS-CoV 4–6 weeks after boosting. n= 12, SARS-
N s.c.; n= 77, SARS-N i.n.; n= 45, GFP i.n. (C) Intranasally vaccinated mice were infected 
with various doses of SARS-CoV. n= 4, GFP 100 PFU; n= 4, SARS-N 100 PFU; n= 10, 
SARS-N 500 PFU; n= 8, SARS-N 104 PFU. (D) Lungs were removed at the indicated times 
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p.i., and sections were stained with hematoxylin and eosin. (E) To obtain virus titers, lungs 
were homogenized at the indicated time points and titered on Vero E6 cells. Titers are 
expressed as PFU/g tissue. n= 3 mice/group/time point. *P <0.05. Data are representative of 
2 independent experiments. (F) VRP-SARS-N vaccinated mice were treated 
intraperitoneally (i.p.) with 1 mg anti-CD4 antibody (clone GK1.5) or rat IgG (rIgG) at day 
-2 and day 0 p.i. (day 2); some mice were rested for 98 days before SARS-CoV infection 
(day 98). n= 5, rIgG i.p. day -2; n= 9, αCD4 i.p. day −2; n= 9, rIgG i.p. day −98; n= 5, 
αCD4 i.p. day −98. (G) Lungs were removed from VRP-SARS-N vaccinated and antibody 
i.p. treated mice at day 4 p.i. Sections were stained with hematoxylin and eosin. (H) 
Numbers of IFN-γ+ CD4+ T cells at several times post boosting are shown. (I) Survival after 
infection with 100 PFU SARS-CoV at 11 and 41 weeks after boosting. n= 9, GFP; n= 5, 
SARS-N 11 weeks; n= 6, SARS-N 41 weeks. (J) 300 μl of immune serum were transferred 
into VRP-GFP vaccinated mice one day before infection. n= 4, GFP serum i.p.; n= 5, SARS-
N serum i.p.; n= 5, SARS-S serum i.p. (K) Mice were vaccinated with rVV-SARS-N or 
irrelevant rVV intravenously (i.v.) or i.n. and boosted 6–7 weeks later. Mice were infected 
with SARS-CoV 4-6 weeks after boosting. n= 5/group. (L) 15 month old VRP-SARS-N 
vaccinated mice were infected with 100 PFU SARS-CoV. n= 5, GFP i.n.; n= 10, SARS-N 
i.n. See also Figures S1, S2 and S6.
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Figure 2. Airway-derived N-specific CD4+ T cells are superior effector cells
(A) To localize memory CD4+ T cells in the respiratory tract at 5–7 weeks after boosting, 
0.25 μg of fluorochrome-conjugated CD45 and 0.5 μg of fluorochrome-conjugated CD90.2 
antibody were injected i.n. and i.v. respectively as described in Experimental Procedures. (B) 
CD4+ T cells from airway, parenchyma and vasculature were stimulated with SARS-CoV 
N353 peptide. Data are representative of 5 independent experiments. (C) Cells from 
vaccinated mice were stained with SARS-N353 tetramer and phenotypic markers at 5–7 
weeks post boosting after simultaneous i.n./i.v. labeling. Data are representative of 2 
independent experiments. (D–G) Vaccinated mice were infected with SARS-CoV at the 
indicated times. Cells were stimulated with SARS-N353 peptide. Frequency, numbers and 
mean fluorescence intensity (MFI) of IFN-γ expression (D) of IFN-γ+ CD4+ T cells or cells 
expressing IFN-γ and TNF, IL-10 or IL-2 (E, F) are shown. *P <0.05. Data are 
representative of 3 independent experiments. (G) Functional avidity of N353-specific CD4+ 
T cells (left) and the amount of peptide required for half-maximum response (EC50) are 
shown (right). *P<0.05. Data are representative of 4 independent experiments. See also 
Figures S3 and S5.
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Figure 3. N-specific airway memory CD4+ T cells mediate protection by local expression of IFN-
γ
(A, B) For local depletion of CD4+ T cells from the airway, mice were treated with 10 μg 
anti-CD4 antibody (clone GK1.5) i.n. in 75 μl PBS at day -1. (A) Mice were simultaneously 
i.n. and i.v. labeled. BALF and lungs were harvested 2 days after depletion. Control mice 
received equivalent doses of rIgG in each experiment. Depletion efficiency was calculated. 
(B) N353 CD4+ T cell numbers were monitored after depletion. n= 3 mice/group/time point. 
Data are representative of 2–4 independent experiments. (C) Airway CD4+ T cells were 
depleted from VRP-SARS-N vaccinated mice with anti-CD4 antibody or rIgG i.n. one day 
prior to SARS-CoV challenge. n= 5, rIgG i.n.; n= 24, αCD4 i.n. (D) IFN mRNA levels in 
the lungs were measured at the indicated time points. n= 3–4 mice/group/time point. 
*P<0.05. Data are representative of 2 independent experiments. (E) CD4+ T cells were 
depleted from VRP-SARS-N vaccinated mice prior to SARS-CoV infection by i.n. or i.p. 
administration of anti-CD4 antibody. IFN-γ RNA levels in the lungs were measured at the 
indicated time points. n= 3–6 mice/group/time point. *P<0.05. Data are representative of 2 
independent experiments. (F) For in vivo ICS, VRP-SARS-N vaccinated mice were treated 
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i.n. with BFA or vehicle at day 4 p.i. After 6 hours, airway CD4+ T cells were analyzed for 
IFN-γ expression. Frequency of IFN-γ+ CD4+ T cells is shown. *P<0.05. Data are 
representative of 2 independent experiments. (G) VRP-SARS-N vaccinated mice were 
treated with 10 μg IFN-γ neutralizing antibody (clone XMG1.2) or rIgG i.n. at day -2, and 
every 2 days thereafter. Lungs were harvested at indicated time points and interferon-related 
gene RNA levels in the lungs were measured. n= 3–6 mice/group/time point. *P<0.05. Data 
are representative of 2 independent experiments. (H) VRP-SARS-N vaccinated mice were 
treated with anti-IFN-γ antibody i.n. Control mice received equivalent doses of rIgG in each 
experiment. n= 5, rIgG; n= 9, αIFN-γ i.p.; n= 7, αIFN-γ i.n. (I) Lungs were removed from 
VRP-SARS-N vaccinated and antibody i.n. treated mice at day 4 p.i. Sections were stained 
with hematoxylin and eosin. (J) To obtain virus titers, mice were treated with antibody i.n. 
and sacrificed at the indicated time points. Titers are expressed as PFU/g tissue. n= 3 mice/
group/time point. *P <0.05. Data are representative of 2 independent experiments. (K) Naïve 
mice were treated with 200 ng rTNF or rIFN-γ 12 hours before SARS-CoV infection. n= 4, 
PBS i.n.; n= 5, rIFN-γ i.n.; n= 4, rTNF i.n. See also Figure S4
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Figure 4. Airway CD4+ T cell-derived IFN-γ is required for optimal rDC migration to the MLNs
(A) To determine rDC migration from the lung to MLN, vaccinated mice were treated with 
anti-CD4 antibody, IFN-γ neutralizing antibody or rIgG i.n. CFSE was then administered i.n. 
6 hours before SARS-CoV infection. The percentage of CFSE+ cells within the 
CD11c+MHCII+ DC population (A, left), total CFSE+ DC numbers per LN (A, right) and 
total LN cell numbers (B) at 18 hours p.i. are shown. *P<0.05. Data are representative of 4 
independent experiments. (C) CD40, CD80, CD86 and CCR7 expression on CFSE+ rDCs in 
the MLN at 18 hours p.i. Isotype control-shaded. (D) Naïve mice were treated with 200 ng 
rIFN-γ i.n. for 12 hours. The frequency of CCR7+ rDCs in lungs is shown. Data are 
representative of 2 independent experiments.
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Figure 5. Airway CD4+ T cell-derived IFN-γ promotes CXCR3-dependent mobilization of virus-
specific CD8+ T cells to the infected lung
Vaccinated mice were infected with SARS- CoV. At day 6 and 8 p.i., cells from lungs were 
stimulated with SARS-S366 peptide for IFN-γ (A) and granzyme B or CD107a/b expression 
(B). (C) In vivo cytotoxicity assays in the lungs were performed on day 6 p.i. using SARS-
CoV CD8+ T cell peptide S366 as described in Experimental Procedures. *P<0.05. Data are 
representative of 3 independent experiments. (D, E) For systemic depletion of CD8+ T cells, 
VRP-SARS-N vaccinated mice were injected i.p. with anti-CD8 or control antibody at day 
-2 and day 0 p.i. Mice were then infected with SARS-CoV and monitored for survival (D) 
(n= 5, rIgG i.p.; n= 7, αCD8 i.p.) or virus titers (E) (n= 3 mice/group/time point. *P<0.05). 
Data are representative of 2 independent experiments. (F) SARS-CoV S366-specific IFN-γ+ 
CD8+ T cell frequency and numbers in the lungs of VRP-SARS-N vaccinated and antibody 
i.n. treated mice at day 6 p.i. (G) Chemokine receptor expression on SARS-CoV S366-
specific CD8+ T cells at day 6 p.i. (H) VRP-SARS-N vaccinated mice were treated with 
anti-CD4 antibody or IFN-γ neutralizing antibody i.n. and infected with SARS-CoV. Lungs 
were assayed for chemokine RNA levels. n= 4–6 mice/group/time point. *P<0.05. Data are 
representative of 2 independent experiments. (I) SARS-CoV challenged, VRP-SARS-N 
vaccinated mice were treated with CXCR3 blocking antibody (clone CXCR3-173) i.p. at day 
3 and 5 p.i. Lung cells were stimulated with SARS-S366 peptide at day 6 p.i. See also 
Figures S2 and S4.
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Figure 6. The N-specific CD4+ T cell epitope is conserved in MERS-CoV and is presented by 
human HLA-DR2 and DR3 molecules
(A) Sequences of SARS-CoV N353 epitope and homologous epitopes in other CoVs are 
shown. Underlined letters are anchor residues. (B) Airway-derived cells were prepared from 
MERS-CoV infected (1 x 105 PFU) mice at day 6 p.i., and stimulated with peptide. 
Frequencies of MERS-CoV specific T cells (determined by IFN-γ intracellular staining) are 
shown. (C) VRP-MERS-N and control vaccinated mice were infected with MERS-CoV and 
sacrificed at the indicated time points. Airway cells were stimulated with MERS-N350 
peptide for intracellular IFN-γ. (D, E) Virus titers were obtained from the lungs of VRP-
MERS-N vaccinated mice (D) or vaccinated and antibody i.n. treated mice (E) at the 
indicated time points p.i. Titers are expressed as PFU/g tissue. n= 3 mice/group/time point. 
*P<0.05. Data are representative of 2 independent experiments. (F) Human HLA class II 
transgenic mice were immunized s.c. with N-specific peptides (100 μg) from SARS-CoV 
(left) or MERS-CoV (right). At 10 days after immunization, lymphocytes prepared from 
draining lymph nodes were stimulated N or control proteolipid protein (PLP) peptides in 
vitro. The results are presented as stimulation indices (cpm of test sample/cpm of the 
control). *P<0.05. Data are representative of 2 independent experiments. (G) HLA-DR2 
mice were vaccinated with VRP-SARS-N (left) or VRP-MERS-N (right) i.n. and infected 
with SARS-CoV or MERS-CoV. Lung virus titers are expressed as PFU/g tissue. n= 3 mice/
group/time point. *P<0.05. Data are representative of 2 independent experiments. See also 
Figure S7.
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Figure 7. Cross-reactive memory CD4+ T cells are protective against SARS-CoV and MERS-
CoV
(A) Airway-derived cells from VRP-MERS-N-vaccinated mice were stimulated with various 
CoV-specific peptides, and assayed for IFN-γ production five days post booster. The 
percentage of cross reactivity between MERS-N peptide and other coronavirus N peptides is 
shown. (B) VRP-MERS-N or VRP-GFP vaccinated mice were infected with SARS-CoV. 
Airway-derived cells were stimulated with SARS-N or MERS-N peptides and assayed for 
IFN-γ production at day 6 p.i. Numbers of CD4+ T cells responding to MERS-N350 or 
SARS-N353 peptides are shown (right panel). *P <0.05. Data are representative of 6 
independent experiments. (C) VRP-MERS-N or VRP-GFP vaccinated mice were infected 
with 100 PFU or 500 PFU of SARS-CoV. n= 4, GFP-immunized + 100 PFU SARS-CoV; n= 
4, GFP + 500 PFU; n= 12, MERS-N + 100 PFU; n= 8, MERS-N + 500 PFU. (D) Mice were 
vaccinated with VRP-HKU4-N. Airway-derived cells were stimulated with CoV-specific 
peptides and assayed for IFN-γ production. The percentage of cross reactivity between 
HKU4-N peptide and other coronavirus N peptides is shown. (E) VRP-HKU4-N or VRP-
GFP vaccinated mice were infected with MERS-CoV. Airway-derived cells were stimulated 
with HKU4-N and MERS-N peptides. Numbers of IFN-γ+ SARS-N353 and MERS-N350-
specific CD4+ T cells are shown (right panel). *P<0.05. Data are representative of 3 
independent experiments. (F) Virus titers in the lungs are expressed as PFU/g tissue. n= 3 
mice/group/time point. *P<0.05. Data are representative of 2 independent experiments.
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